Log in

NASDAQ:VSTMVerastem Stock Price, Forecast & News

$1.48
-0.05 (-3.27 %)
(As of 08/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.47
Now: $1.48
$1.58
50-Day Range
$1.32
MA: $1.57
$1.91
52-Week Range
$0.83
Now: $1.48
$4.67
Volume3.35 million shs
Average Volume4.83 million shs
Market Capitalization$240.54 million
P/E RatioN/A
Dividend YieldN/A
Beta1.09
Verastem, Inc., a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being investigated in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), mesothelioma, and other solid tumors. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited. The company was founded in 2010 and is headquartered in Needham, Massachusetts.
Read More
Verastem logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:VSTM
CUSIP92337C10
Phone781-292-4200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.46 million
Book Value$0.09 per share

Profitability

Net Income$-149,210,000.00
Net Margins-715.40%

Miscellaneous

Employees169
Market Cap$240.54 million
Next Earnings DateN/A
OptionableOptionable
$1.48
-0.05 (-3.27 %)
(As of 08/6/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VSTM News and Ratings via Email

Sign-up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Verastem (NASDAQ:VSTM) Frequently Asked Questions

How has Verastem's stock been impacted by COVID-19 (Coronavirus)?

Verastem's stock was trading at $2.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, VSTM shares have decreased by 39.3% and is now trading at $1.48.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Verastem?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Verastem
.

How were Verastem's earnings last quarter?

Verastem Inc (NASDAQ:VSTM) released its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.22) by $0.13. The biopharmaceutical company had revenue of $5.06 million for the quarter, compared to analyst estimates of $3.14 million. Verastem had a negative return on equity of 282.13% and a negative net margin of 715.40%.
View Verastem's earnings history
.

What price target have analysts set for VSTM?

2 analysts have issued 12 month price objectives for Verastem's stock. Their forecasts range from $3.00 to $6.00. On average, they expect Verastem's share price to reach $4.50 in the next twelve months. This suggests a possible upside of 204.1% from the stock's current price.
View analysts' price targets for Verastem
.

Has Verastem been receiving favorable news coverage?

News stories about VSTM stock have been trending positive this week, InfoTrie reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Verastem earned a media sentiment score of 2.1 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about Verastem
.

Who are some of Verastem's key competitors?

What other stocks do shareholders of Verastem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), Amarin (AMRN), Exelixis (EXEL), Synergy Pharmaceuticals (SGYP) and TG Therapeutics (TGTX).

Who are Verastem's key executives?

Verastem's management team includes the following people:
  • Mr. Robert Forrester, Pres, CEO & Director (Age 55)
  • Mr. Robert E. Gagnon, Chief Financial Officer (Age 45)
  • Mr. Joseph M. Lobacki, Exec. VP & Chief Commercial Officer (Age 61)
  • Mr. Richard H. Aldrich M.B.A., Mba, Founder and Consultant (Age 65)
  • Dr. Robert A. Weinberg, Co-Founder and Chair of Scientific Advisory Board

What is Verastem's stock symbol?

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

Who are Verastem's major shareholders?

Verastem's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Swiss National Bank (0.15%), Virtus ETF Advisers LLC (0.12%), UBS Group AG (0.10%), Creative Planning (0.07%), Matisse Capital (0.06%) and Samalin Investment Counsel LLC (0.02%). Company insiders that own Verastem stock include Dan Paterson, Joseph M Lobacki, Michael Kauffman, Ra Capital Management, LP, Robert Forrester and Timothy J Barberich.
View institutional ownership trends for Verastem
.

Which institutional investors are selling Verastem stock?

VSTM stock was sold by a variety of institutional investors in the last quarter, including Matisse Capital, Creative Planning, and Raymond James Financial Services Advisors Inc..
View insider buying and selling activity for Verastem
.

Which institutional investors are buying Verastem stock?

VSTM stock was bought by a variety of institutional investors in the last quarter, including Swiss National Bank, Virtus ETF Advisers LLC, UBS Group AG, Arizona State Retirement System, ProShare Advisors LLC, Principal Financial Group Inc., WESPAC Advisors SoCal LLC, and Ameritas Investment Partners Inc.. Company insiders that have bought Verastem stock in the last two years include Dan Paterson, Joseph M Lobacki, Michael Kauffman, Robert Forrester, and Timothy J Barberich.
View insider buying and selling activity for Verastem
.

How do I buy shares of Verastem?

Shares of VSTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Verastem's stock price today?

One share of VSTM stock can currently be purchased for approximately $1.48.

How big of a company is Verastem?

Verastem has a market capitalization of $240.54 million and generates $17.46 million in revenue each year. The biopharmaceutical company earns $-149,210,000.00 in net income (profit) each year or ($2.00) on an earnings per share basis. Verastem employs 169 workers across the globe.

What is Verastem's official website?

The official website for Verastem is www.verastem.com.

How can I contact Verastem?

Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The biopharmaceutical company can be reached via phone at 781-292-4200 or via email at [email protected]

This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.